ndothelial injury in the kidney has been shown to correlate with the progression of glomerular and tubulointerstitial damage (1) . The observations that administration of vascular endothelial growth factor enhances capillary repair and improves renal function in several experimental models (2) (3) (4) suggest that therapy that is aimed at stimulating capillary repair may slow the progression of renal diseases.
Recent evidence indicates that bone marrow-derived endothelial progenitor cells contribute to tissue vascularization after ischemic events such as hindlimb arterial occlusion and myocardial infarction (5) . On the basis of their roles in the response to injury, bone marrow-derived endothelial progenitor cells have been isolated and transplanted for therapeutic applications, and enhancement of re-endothelialization and restoration of organ function have been observed in cardiac and hindlimb ischemia and carotid artery injury (5, 6) .
A recent report showed endothelial progenitor cells mobilized from the bone marrow also to contribute to glomerular endothelial repair in anti-Thy1.1 glomerulonephritis (7), a model characterized by mesangial and glomerular endothelial injury (8) . However, the therapeutic potential of exogenously administered bone marrow-derived cells, including endothelial progenitor cells, for endothelial injury in the kidney has not been clarified. We, therefore, investigated whether administration of culture-modified bone marrow mononuclear cells (CMMC), which had been prepared using a method designed to obtain endothelial progenitor cells, were capable of attenuating endothelial damage and mesangial activation in anti-Thy1.1 glomerulonephritis. Because recent evidence suggests that the production of angiogenic factors also contributes to re-endothelialization by exogenously administered endothelial progenitor cells (9 -11) , we further investigated whether CMMC secrete vascular endothelial growth factor (VEGF), an angiogenic factor that re-portedly enhances glomerular endothelial repair in experimental glomerulonephritis (3) .
Materials and Methods

Cell Culture
CMMC were isolated and cultured according to a previously described method used for isolation of endothelial precursor cells from bone marrow (12, 13) . In brief, bone marrow mononuclear cells were isolated from the femurs and tibias of 6-wk-old male Lewis rats (CLEA Japan, Tokyo, Japan) by density gradient centrifugation with FicollPaque Plus (Amersham Biosciences). The obtained cells were cultured in DMEM supplemented with 10% FBS, 50 g/ml heparin, 10 ng/ml recombinant human VEGF (R&D Systems, Minneapolis, MN), 5 ng/ml fibroblast growth factor-2 (R&D Systems), 100 g/ml streptomycin, and 500 g/ml penicillin, on fibronectin-coated dishes.
Adherent cells after 5 or 6 d of culture were infused into nephritic rats, as CMMC. The cells were labeled with a fluorescence marker, CM-DiI (Molecular Probes, Eugene, OR), by incubation in PBS that contained 3 g/ml CM-DiI for 5 min at 37°C and 15 min at 4°C. After being detached from the dishes by addition of 3 mM EDTA solution and a minimal amount of trypsin, cells were passed through a cell strainer (Falcon) and injected into the nephritic rats.
For the determination of endothelial lineage characteristics (5, 14) , CMMC that were cultured for 6 d were evaluated for the uptake of acetylated LDL, the binding of Bandeiraea simplicifolia lectin (BS-1), and VEGF receptor 2 (VEGF-R2) expression. After incubation with 10 g/ml DiI-labeled acetylated LDL (Biogenesis Ltd., Poole, UK) for 1 h, cells were fixed in 2% paraformaldehyde, stained with 100 g/ml FITC-labeled BS-1 (Sigma, St. Louis, MO), and examined by fluorescence microscopy. For measuring VEGF-R2 expression, CMMC were fixed in ice-cold methanol and stained with a rabbit polyclonal antibody against VEGF-R2 (Santa Cruz Biotechnology, Santa Cruz, CA; dilution 1:200) as the primary antibody. After incubation with Alexa Fluor 488 goat anti-rabbit IgG (Molecular Probes) as the secondary antibody at a dilution of 1:200, the cells were analyzed by confocal laser-scanning microscopy (Leica DMIR/E2 TCS SL; Leica GmbH, Wetzlar, Germany). Negative controls included nonimmune rabbit IgG (Cedarlane Laboratories, ON, Canada) instead of the primary antibody.
Experimental Protocol
Anti-Thy1.1 glomerulonephritis was induced in 6-wk-old female Lewis rats by injection of 250 g/100 g body wt monoclonal antibody 1-22-3 (15) into the tail vein. Control rats received a saline injection instead of the antibody (n ϭ 6). One day after the injection of monoclonal antibody 1-22-3, cultured CMMC (1.0 Ϯ 0.2 ϫ 10 6 ) in 1 ml of PBS were injected into the left renal artery (n ϭ 6). Four nephritic rats were monitored in parallel without CMMC injection for analysis of renal function. Twenty-four-hour urine collections were performed on day 5 after the antibody injection. Urinary protein concentrations were determined with a pirogarol-red method kit (Wako Chemistry Co., Ltd., Tokyo, Japan). Seven days after the induction of glomerulonephritis, the kidneys were perfused with saline and removed from anesthetized animals. Blood was collected when the rats were killed for determination of serum creatinine concentrations. For morphologic analysis and immunohistochemical staining for ␣-smooth muscle actin (␣-SMA) and ED-1, coronal sections of renal tissue were immersion-fixed in 10% neutral-buffered formalin and embedded in paraffin. 
Renal Morphology
For assessing morphologic changes, 4-m paraffin sections were stained with periodic acid-Schiff (PAS) reagent and hematoxylin and examined by normal light microscopy. Semiquantitative morphologic studies of glomerular lesions were performed on 25 glomeruli randomly selected from each specimen by one of the authors, each author being unaware of the origins of the slides. The degree of glomerular mesangial cell and/or matrix expansion was graded according to the percentage of glomerular involvement as described previously (16) using the following criteria: 0 ϭ normal glomerular cellularity with no significant mesangial expansion; 1ϩ ϭ mesangial cell and/or matrix expansion involving Ͻ25% of the glomerular area; 2ϩ ϭ mesangial cell and/or matrix expansion involving 26 to 50% of the glomerular area; 3ϩ ϭ mesangial cell and/or matrix expansion involving 51 to 75% of the glomerular area; and 4ϩ ϭ diffuse (Ͼ75% of the glomerular area) mesangial cell and/or matrix expansion or a glomerulus showing basement membrane disruption and/or mesangiolysis.
Immunohistochemical Staining and Quantitative Analysis
Glomerular endothelial injury was evaluated by immunofluorescent staining for RECA-1 and analysis of glomerular capillary density, according to a previously described method (17) , with minor modification. Frozen sections, 6 m thick, were stained with mouse anti-RECA-1 monoclonal antibody (Serotec Ltd., Oxford, UK; dilution 1:20) as the primary antibody. Alexa Fluor 488 goat anti-mouse IgG (Molecular Probes) was used as the secondary antibody at a dilution of 1:200. Sections then were analyzed by confocal laser-scanning microscopy (Leica DMIR/E2 TCS SL). Glomerular capillaries, identified by positive staining for RECA-1, were counted, and the glomerular tuft area was calculated by image analysis using Adobe Photoshop 7.0 and Scion Image. After evaluation of 20 glomeruli from each kidney in a blinded manner, the glomerular capillary density was normalized to the number of capillaries per square millimeter.
For the detection of ␣-SMA, deparaffinized sections, 4 m thick, were stained with mouse anti-␣-SMA monoclonal antibody (1A4; DakoCytomation Co. Ltd.; 1:50 dilution), according to a previously described method (18) , with minor modification. Immobilized antibody was detected by the biotin-avidin-immunoperoxidase technique using a Vectastain Elite ABC kit (Vector Laboratories, Burlingame, CA) and 3-3Ј-diaminobenzidine as the chromogen. Sections then were counterstained with Mayer's hematoxylin and examined by light microscopy. The ratio of the glomerular ␣-SMA-positive area to the glomerular tuft area was calculated by image analysis using Nikon ACT-1 version 220, Adobe Photoshop 7.0, and Scion Image. The mean value of the ␣-SMA-positive area was calculated by evaluating 20 glomeruli from each kidney in a blinded manner.
Glomerular infiltration of macrophages was determined by counting the number of ED-1-positive cells according to a previously described method (19) , with minor modification. Deparaffinized sections, 4 m thick, were stained with mouse anti-rat macrophage monoclonal antibody, clone ED-1 (Chemicon International, Temecula, CA) at a dilution of 1:100. Immobilized antibody was detected by the biotin-avidinimmunoperoxidase technique using an LSAB kit (DakoCytomation Co. Ltd.) and 3-3Ј-diaminobenzidine as the chromogen. Sections then were counterstained with Mayer's hematoxylin and examined by light microscopy. The number of ED-1-positive cells in glomerular cross-sec-tions was counted in a blinded manner in at least 30 glomeruli for each section, and mean values per kidney were calculated.
Incorporation of CMMC was investigated using fluorescence microscopy. The rate of glomeruli positive for CM-DiI-labeled cells was calculated by dividing the number of glomeruli that contained CMDiI-labeled cells by the total number of glomeruli examined. The number of CM-DiI-labeled cells per glomerulus, in glomeruli with these cells, was also determined. At least 50 glomeruli per kidney were examined, and the mean number was obtained from six kidneys.
For evaluating the possibility of differentiation of CMMC into mesangial cells, frozen sections, 6 m thick, were stained with mouse anti-CD90 monoclonal antibody, clone MRC OX-7 (Serotec Ltd; dilution 1:800) followed by Alexa Fluor 488 goat anti-mouse IgG (Molecular Probes) at a dilution of 1:1000. For the determination of possible differentiation of CMMC into macrophages, deparaffinized sections, 4 m thick, were stained with anti-rat macrophage antibody, clone ED-1. The sections then were incubated with Alexa Fluor 488 goat anti-mouse IgG (Molecular Probes) at a dilution of 1:200. After staining of nuclei with TO-PRO-3 (Molecular Probes), sections were analyzed by confocal laser-scanning microscopy. At least 20 DiI-positive cells per kidney were evaluated for staining with anti-RECA-1 antibody, OX-7, or ED-1. The mean positive rate was obtained by examining five rats. Negative controls for immunohistochemical staining included substitution of the primary antibody with an irrelevant mouse IgG or PBS.
ELISA Assay
Culture supernatants of freshly obtained bone marrow mononuclear cells were collected after incubation in the presence of endothelial growth factors for 4 d. After removal of the nonadherent cells, CMMC were further incubated, and the culture supernatants from days 6 to 9 then were collected. Rat VEGF content in the culture supernatants was determined with a murine VEGF ELISA kit (R&D Systems), using rat VEGF (R&D Systems) as a standard. Cross-reactivity to human VEGF was negligible under our assay conditions. VEGF production was expressed as the amount of VEGF produced per day divided by the cell number at the start of incubation. Cell number on day 6 was obtained by counting trypsinized cells that had been treated in a manner identical to that of cells that were subjected to further incubation.
Statistical Analyses
All data are expressed as means Ϯ SEM. Multiple parametric comparisons were performed using ANOVA, followed by Fisher protected least significant difference test. Comparisons between two groups were performed by t test. P Ͻ 0.05 was considered statistically significant.
Results
Characterization of CMMC
After a 6-d culture in the presence of endothelial growth factors, Ͼ90% adherent bone marrow cells had incorporated acetylated LDL and stained positive for BS-1 lectin (Figure 1) . Endothelial progenitor cells from various sources have been shown to have these characteristics (5, 13, 14, 20, 21) . In contrast, before culture, Ͻ5% of bone marrow mononuclear cells showed incorporation of acetylated LDL (data not shown). CMMC also expressed VEGF-R2, a marker for endothelial-lineage cells (5) .
Attenuation of Glomerular Endothelial Cell Injury by Administration of CMMC
The effect of CMMC on glomerular endothelial injury in anti-Thy1.1 nephritis was investigated by injecting 1.0 Ϯ 0.2 ϫ
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6 CM-DiI-labeled cells into the left renal arteries of rats (n ϭ 6) 1 d after anti-Thy1.1 antibody injection. In agreement with previously published observations (17, 22, 23) , glomerular RECA-1-positive capillary density was decreased at 7 d after anti-Thy1.1 antibody injection (Figure 2) . Compared with the right kidney, the decrease in glomerular capillary density was significantly attenuated in the left kidneys of nephritic rats that had received CMMC infusions into the left renal artery.
Attenuation of Mesangial Activation by Administration of CMMC
Glomerular architecture evaluated by PAS staining 7 d after anti-Thy1.1 antibody injection showed mesangial hypercellularity, focal mesangiolysis, and marked expansion of the extracellular matrix. Glomeruli in the left kidney, into which CMMC had been injected 1 d after the injection of anti-Thy1.1 antibody, showed less expansion of the mesangial area than those in the right kidney, as judged from semiquantitative histologic analysis (Figure 3) . The increase in expression of glomerular ␣-SMA, a marker of activated mesangial cells (24) , was also significantly reduced by administration of CMMC. Glomerular infiltration of macrophages, as assessed by counting the number of glomerular ED-1-positive cells, induced in nephritic rats was also attenuated by injection of CMMC, as shown in Figure 4 . No labeled cells were observed in right kidneys that were obtained from the same rats (data not shown). Among the CM-DiI-labeled cells that were incorporated into glomeruli, 16.5 Ϯ 1.2% of cells were stained with RECA-1. As shown in Figure 6 , A through C, some RECA-1-positive CMMC participated in capillary formation together with the adjacent endothelial cells. In addition to the CMMC showing strong RECA-1 staining, there were some CMMC that stained only weakly with RECA-1 ( Figure 6 , D through F). The latter cells, however, seemed to be forming connections with adjacent endothelial cells. A few labeled cells that were positive for RECA-1 were also observed in the interstitial space (data not shown).
Incorporation of CMMC into Glomeruli and Expression
To evaluate whether CMMC may have differentiated into glomerular components other than endothelial cells, we stained the sections with OX-7 and ED-1, markers of mesangial cells and macrophages, respectively. Although CM-DiI-positive cells were negative for OX-7 ( Figure 6 , G through I), 21.8 Ϯ 7.0% of cells were stained with ED-1 ( Figure 6 , J through L). The CM-DiI signals in ED-1-positive cells, however, were mostly granular in character and not homogeneously distributed, as in labeled CMMC just before injection.
Proteinuria and Serum Creatinine Concentrations
Proteinuria was mildly increased in Lewis rats that received anti-Thy1.1 antibody as compared with control rats and was not significantly altered by CMMC injection, although a tendency for reduction was observed (normal control rats, 1.2 Ϯ 0.6 mg/24 h; nephritic rats, 14.4 Ϯ 3.9 mg/24 h; nephritic rats Figure 2 . Magnification, ϫ400 treated with CMMC, 12.9 Ϯ 2.1 mg/24 h). Serum creatinine concentrations were not significantly changed on day 7 after the injection of anti-Thy1.1 antibody under our experimental conditions (normal control rats, 0.30 Ϯ 0.02 mg/dl; nephritic rats, 0.28 Ϯ 0.04 mg/dl).
VEGF Production by CMMC
To explore the possible contribution of angiogenic factors produced by CMMC to their renoprotective effects, we investigated whether CMMC secrete VEGF in vitro. CMMC did produce VEGF, and the amount of VEGF secreted was markedly increased as compared with that produced by freshly derived bone marrow mononuclear cells (Figure 7) , suggesting that cells with angiogenic potential had been selectively grown under our culture conditions.
Discussion
This study demonstrated intrarenal injection of CMMC to ameliorate glomerular endothelial injury in anti-Thy1.1 glomerulonephritis. Loss of glomerular endothelial cells has been observed in several models of progressive renal disease and correlates with the development of glomerulosclerosis (1, 17, 25) . Because an imbalance between pro-angiogenic and anti-angiogenic factors in the intrarenal microenvironment has been suggested to play a role in endothelial loss (1), administration of angiogenic factors was expected to have a protective effect against progressive renal diseases. Indeed, VEGF and hepatocyte growth factor have been shown to accelerate repair of glomerular endothelial cells and stabilize renal function when injected into models of glomerular injury (2) (3) (4) 26) . Our data demonstrate that injection of CMMC is another approach to maintaining glomerular endothelial cells in glomerulonephritis.
Protective effects of CMMC were also observed in the mesangial area. The observation that glomerular expression of ␣-SMA was inhibited by injection of CMMC indicates that activation of mesangial cells was attenuated. In accordance with the results of ␣-SMA staining, expansion of the mesangial area, as assessed by PAS staining, was also attenuated by administration of CMMC. Preservation of the endothelial population by cell therapy is likely to contribute to attenuating mesangial cell activation, possibly through preventing direct exposure of mesangial cells to the microcirculation and via the production of anti-inflammatory factors. In addition, direct effects of CMMC on mesangial cells may be involved. In addition to endothelial injury and mesangial activation, glomerular infiltration of macrophages was also attenuated by CMMC treatment. This finding is in accordance with previous reports demonstrating the protective effects of angiogenic factors against the progression of glomerulonephritis (3, 26) and supports the notion that protecting glomerular endothelial cells may attenuate the inflammation in glomerulonephritis. Although we observed improvement in glomerular histologic changes, proteinuria was not significantly reduced by CMMC injection. Treatment of just one kidney with CMMC may not have been sufficient for a significant reduction in proteinuria.
CMMC had some of the characteristics of endothelial-lineage cells (5), including uptake of acetylated LDL, binding to BS-1 lectin, and expression of VEGF-R2. After administration to nephritic rats, CM-DiI-labeled CMMC were incorporated into the glomerular microvasculature and a significant number, although not all, cells stained positive for RECA-1, a mature endothelial cell marker. These observations suggest that some CMMC act as endothelial progenitor cells, although fusion of the injected CMMC with glomerular endothelial cells cannot be ruled out. The finding that CMMC stained for RECA-1 with different intensities, together with the observation that no CMMC before injection showed strong positive staining for RECA-1 (data not shown), suggests that CMMC 6 d after injection may be at various stages of maturation into RECA-1-positive endothelial cells in response to local cues in the injured glomeruli.
Glomerular capillary density in kidneys that were treated with CMMC was approximately three times higher than that in kidneys without cell infusion. This improvement cannot be explained solely by the direct incorporation of CMMC into the glomerular endothelial lining, considering the proportion of RECA-1-positive CMMC incorporated into glomeruli. In addition to differentiating into mature endothelial cells, exogenously administered endothelial progenitor cells, prepared by culturing bone marrow-derived mononuclear cells under conditions of endothelial differentiation, have been suggested to exert their angiogenic effects by producing angiogenic factors (9 -11). Recent evidence also suggests that the beneficial effects of hematopoietic stem cell therapy on cardiac function after ischemia may be due to the angiogenic activities of the injected cells rather than transdifferentiation, originally thought to be important (27, 28) . Because an in vitro experiment revealed that CMMC produced a significant amount of VEGF, VEGF secreted by CMMC in glomeruli is likely to stimulate endothelial growth in a paracrine manner and contribute to the prevention of endothelial cell loss. The amount of VEGF produced by CMMC (281.2 Ϯ 85.0 pg/10 5 cells per d) was comparable to that reportedly produced by cells that were used for angiogenic cell therapy (40 to 260 pg/10 5 cells per d) (11, 29) . Local production of VEGF by CMMC incorporated in injured glomeruli may also induce recruitment of endogenous endothelial progenitor cells, because this angiogenic factor is known to promote mobilization of endothelial progenitor cells (5) . Other angiogenic factors such as hepatocyte growth factor, the mRNA of which was detected by reverse transcription-PCR in CMMC (data not shown), may also be involved in the angiogenic activities of CMMC. The roles of these angiogenic factors, however, are still only speculative and remain to be clarified by experiments on specific inhibitory approaches.
Although VEGF has been shown to be effective for prevention and treatment of renal injury in various models, systemic administration of angiogenic factors may exacerbate pathologic angiogenesis, e.g., diabetic retinopathy and tumors (1) . Local infusion of angiogenic cells is expected to circumvent such detrimental effects by acting in the microenvironment where the cells are incorporated. By infusing CMMC into the left renal artery, selective delivery and incorporation of CMMC in the left but not the right kidney in the same animal was achieved. This finding suggests the potential of this therapy for selective modification of the local environment, although it remains to be determined whether such a selective delivery system would work even in the presence of pathologic angiogenesis.
The lack of CMMC staining with OX-7 indicates that CMMC did not contain progenitors of mesangial cells under our experimental conditions. Because some CM-DiI-positive cells stained positive for ED-1, these cells may have differentiated into macrophages. However, because the CM-DiI signals obtained were mostly granular, these signals probably represent, in large part, the debris of injected CMMC that did not survive and were phagocytosed by macrophages. In addition, because macrophages have been shown to induce glomerular matrix expansion in anti-Thy1.1 glomerulonephritis (30), the finding that CMMC attenuated expansion of the mesangial area (Figure 3) indicates that functionally active macrophages possibly derived from CMMC were, if present, minimal.
In conclusion, injection of bone marrow mononuclear cells, after culture under conditions that promote endothelial progenitor cell growth, into the renal artery attenuated glomerular endothelial injury and mesangial activation in anti-Thy1.1 glomerulonephritis. Injected cells exerted angiogenic effects in injured glomeruli probably by being incorporated into the glomerular endothelial lining and by producing angiogenic factor(s). Injecting bone marrow-derived angiogenic cells into the kidney may represent a novel therapeutic approach for glomerular injury associated with endothelial loss and mesangial activation.
